These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10381495)

  • 41. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
    Niitsu N; Umeda M; Shirai T
    Nihon Ronen Igakkai Zasshi; 1993 Sep; 30(9):753-8. PubMed ID: 7693992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
    Osby E; Hagberg H; Kvaløy S; Teerenhovi L; Anderson H; Cavallin-Stahl E; Holte H; Myhre J; Pertovaara H; Björkholm M;
    Blood; 2003 May; 101(10):3840-8. PubMed ID: 12531794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
    Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
    Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
    Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
    Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
    Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
    Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
    J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
    Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
    J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
    Okabe M; Maekawa I; Suzuki S; Higuchi M; Morioka M; Nishi K; Itaya T; Ohmura T; Kawamura M; Fuzimoto N
    Leuk Lymphoma; 1995 Nov; 19(5-6):485-91. PubMed ID: 8590851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
    Bellesi G; Rigacci L; Alterini R; Bernardi F; Stefanacci S; Innocenti F; Fusco II; Longo G; Di Lollo S; Ferrini PR
    Leuk Lymphoma; 1996 Feb; 20(5-6):475-80. PubMed ID: 8833406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.